Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia
Table 1
Cognitive outcome measures of Zembrin effects on neurobattery tests after 3 weeks of Zembrin treatment and placebo treatment.
Outcome measure
Mean score and SEM at baseline and after Zembrin and after placebo treatment